Repligen corp stock.
Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ...
Die Repligen Corp. Aktie wird unter der ISIN US7599161095 an den Börsen Frankfurt, Düsseldorf, München, Stuttgart, Berlin, NASDAQ, Bats, BX World, NASDAQ Bsc, Gettex, Tradegate, Lang & Schwarz ...View the latest Repligen Corp. (RGEN) stock price, news, historical charts, analyst ratings and financial information from WSJ.Repligen Corp’s Stock Price as of Market Close. As of April 12, 2023, 4:00 PM CST, Repligen Corp’s stock price was $179.70. Repligen Corp is up 5.46% from its previous closing price of $170.39. During the last market session, Repligen Corp’s stock traded between $166.22 and $171.25.Repligen Corp (RGEN-1.40%) Q3 ... 10 stocks we like better than Repligen When o ur award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for ...
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 63.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.See the latest Repligen Corp stock price (RGEN:XNAS), related news, valuation, dividends and more to help you make your investing decisions.Repligen Corp ( RGEN) receives a weak valuation ranking of 32 from InvestorsObserver data analysis. The proprietary ranking system focuses on the underlying health of a company through analysis of its stock price, earnings, and growth rate. RGEN has a better value than 32% of stocks based on these valuation analytics.
RGEN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.
... Stock Ideas · Long Ideas · Healthcare. Revisiting Repligen. May 11, 2022 11:31 AM ETRepligen Corporation (RGEN)7 Comments 3 Likes. Another Mountain's ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. ... Stocks Rankings for ...4 thg 4, 2016 ... Once you've won approval for a biologic, or biosimilar, manufactured at a particular facility, you can't just switch to another without jumping ...
The stock’s lowest price was $157.58 before closing at $157.00. Repligen Corp. experienced a somewhat shaky performance in the stock market. The company’s stock reached a 1-year high of $200.98 on 02/16/23, while the lowest price for the same period was registered at $110.45 on 10/30/23.
Find the latest Repligen Corporation (RGEN) stock quote, history, news and other vital information to help you with your stock trading and investing.
Reports revenue of $200.7 million for the quarter, representing year-over-year growth of 13% as reported, 19% at constant currency and 16% organic Delivers base business growth of 29% for the quarter Expands Process Analytics portfolio with DRS Daylight Solutions agreement WALTHAM, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) - …www .repligen .com. Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. 2014 The company is based in Waltham, Massachusetts, 2014 and incorporated in Delaware in 1981. [1] A public company, Repligen is listed on the NASDAQ exchange under the symbol RGEN. [2]Repligen Corp. - RGEN STOCK NEWS . IMPACT. SENTIMENT. 11/14/2023 02:01 PM. RGEN: Nasdaq ... Repligen Corp. Nasdaq:RGEN. RGEN Rankings #1033 Ranked by Market Cap #4078 Ranked by Stock Gains. N/A Ranked by Dividends. RGEN Stock Data. Industry Biological Product (except Diagnostic) Manufacturing .Oct 20, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 18.68% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Repligen Corp’s Stock Price as of Market Close. As of April 12, 2023, 4:00 PM CST, Repligen Corp’s stock price was $179.70. Repligen Corp is up 5.46% from its previous closing price of $170.39. During the last market session, Repligen Corp’s stock traded between $166.22 and $171.25.Quotes Summary Real-Time Live After-Hours Key Data Bid Price and Ask Price The bid & ask refers to the price that an investor is willing to buy or sell a stock. The bid is the …Oct 25, 2023 · Repligen Corp Stock Price History. Repligen Corp’s price is currently down 21.75% so far this month. During the month of October, Repligen Corp’s stock price has reached a high of $164.24 and a low of $124.12. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $134.64. Year to date, Repligen Corp’s stock is ...
Repligen Corporation is a global company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are 'inspiring advances in bioprocessing' for the customers we serve; primarily biopharmaceutical drug developers and contract ...Repligen Corp’s ( RGEN) price is currently down 7.18% so far this month. During the month of September, Repligen Corp’s stock price has reached a high of $179.27 and a low of $159.54. Over the last year, Repligen Corp has hit prices as high as $235.06 and as low as $134.64. Year to date, Repligen Corp’s stock is down 39.05%.Dec 2, 2023 · With Repligen stock trading at $164.94 per share, the total value of Repligen stock (market capitalization) is $9.21B. Repligen stock was originally listed at a price of $0.78 in Dec 31, 1997 . If you had invested in Repligen stock at $0.78 , your return over the last 25 years would have been 21,019.08% , for an annualized return of 23.88% (not ... With stocks at historic highs, many individuals are wondering if the time is right to make their first foray in the stock market. The truth is, there is a high number of great stocks to buy today. However, you might be unsure how to begin.RGEN stock, belonging to Repligen Corp, has shown promising performance on October 31, 2023, based on the information provided. The data source for this analysis is CNN Money. According to the 13 analysts, the median target price for Repligen Corp is $195.00. The high estimate is $240.00, while the low estimate stands …Repligen Corporation is a life sciences company, which develops and commercializes bioprocessing technologies and systems that rises flexibility in the process of manufacturing biological drugs. The Company's bioprocessing business consist of four franchises, filtration; chromatography; process analytics; and proteins.Repligen does not undertake to update, ... 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 ...
Aug 2, 2022 · Shares of the bioprocessing giant Repligen Corporation ( RGEN 4.89%) are glowing green today. Specifically, the biotech's stock was up by as much as 14.9% earlier today. Repligen's shares have ... 7.05%. Trailing 12-Months. The Repligen Holdings stock analysis is based on the TipRanks Smart Score which is derived from 6 unique data sets including Analyst recommendations, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA. RGN | Complete Repligen Corp. stock news by MarketWatch. View real-time stock ...Stock Price Forecast The 13 analysts offering 12-month price forecasts for Repligen Corp have a median target of 170.00, with a high estimate of 210.00 and a low estimate of 148.00.Information on stock, financials, earnings, subsidiaries, investors, and executives for Repligen. Use the PitchBook Platform to explore the full profile. ... Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies an. Biotechnology. Waltham, MA. 2,025 As of 2022 00000000. 000000.Sep 22, 2023 · Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%. Feb 22, 2023 · Total revenue as reported for the full year 2022 increased to $801.5 million compared to $670.5 million for the full year 2021, a year-over-year gain of 20%, or 25% at constant currency, overall ... Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 30.36% in the past year. Currently, Repligen Corp’s price-earnings ratio is 63.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 24.63% in the past year. Currently, Repligen Corp’s price-earnings ratio is 60.3. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp stock has a Value Score of 4, Growth Score of 82 and Momentum Score of 43. Comparing Medtronic PLC and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk …Stock RGEN November 29, 2023 NASDAQ 20 minutes delay $160.44 3.54 (2.256%) Open 157.9 ... Repligen Corporation | 28,921 followers on LinkedIn. FRAUD ALERT: Please take note that it has come to our ...Stocks of Repligen Corp. saw a sharp rise in short interest on Nov 14, 2023 jumping by 10000.0 shares to 5.99 million. Data from Yahoo Finance shows that the short interest on Oct 12, 2023 was 5.98 million shares. A jump of 0.17% in short interest reflects a negative sentiment towards the stock. Despite the fact that short shares comprise just ...Repligen Corp (RGEN-1.40%) Q3 ... 10 stocks we like better than Repligen When o ur award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for ...Complete Repligen Corp. stock information by Barron's. View real-time RGEN stock price and news, along with industry-best analysis.Basic Membership Access to Journal, Shadow Stock portfolio & monthly updates for stock screens; A+ Investor Full access to AAII.com, Journal, and a power data suite for investment ideas; AAII Platinum Full access to all of AAII's model portfolios and premium services at a significant discount; Dividend Investing Newsletter and model …Repligen Corp stock has a Value Score of 5, Momentum Score of 54 and Estimate Revisions Score of 37. Comparing Agiliti Inc and Repligen Corp’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk ...Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. ... Stocks Rankings for ...Repligen Corp. Stock , RGEN 157.24 -0.01 -0.00% After-market 04:44:59 PM EDT 11/30/2023 NAS Add to watchlist 157.25 -2.24 -1.40% Official Close 04:00:00 …Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 22.25% in the past year. Currently, Repligen Corp’s price-earnings ratio is 66.4. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.
Repligen Corp Stock Price History. Repligen Corp’s price is currently up 12.18% so far this month. During the month of November, Repligen Corp’s stock price has reached a high of $152.22 and a low of $126.86. Over the last year, Repligen Corp has hit prices as high as $212.17 and as low as $110.45. Year to date, Repligen Corp’s stock is ...Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 27.1% in the past year. Currently, Repligen Corp’s price-earnings ratio is 68.5. Repligen Corp’s trailing 12-month revenue is $729.3 million with a 18.9% net profit margin. Year-over-year quarterly sales growth most recently was -23.3%.Repligen does not undertake to update, ... 2022, the Company had the option to settle the conversion of the 2019 Notes in cash, stock or a combination of the two. Therefore, from January 1, 2022 ...Instagram:https://instagram. opera singer bocellibest broker day tradinghow do i sell my stocks on robinhoodcsx nasdaq Inspire Medical Systems Inc. 151.72. +6.41. +4.41%. Get Repligen Corp (RGEN:NASDAQ) real-time stock quotes, news, price and financial information from CNBC. voo buy or sellweekend dow ig Repligen Corp’s stock is NA in 2023, NA in the previous five trading days and down 2.91% in the past year. Currently, Repligen Corp’s price-earnings ratio is 65.0. Repligen Corp’s trailing 12-month revenue is $801.3 million with a 20.8% net profit margin. Year-over-year quarterly sales growth most recently was 12.6%. small cap investing 6 hours ago · According to 7 analyst offering 12-month price targets in the last 3 months, Repligen has an average price target of $186.71 with a high of $210.00 and a low of $165.00. Dec 1, 2023 · View Repligen Corporation RGEN investment & stock information. Get the latest Repligen Corporation RGEN detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.